Advertisement

Topics

Post Menopausal Osteoporosis - Pipeline Review, H1 2015

05:01 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Post Menopausal Osteoporosis - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 86-page report is available in PDF from $2000.

Post Menopausal Osteoporosis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Post Menopausal Osteoporosis - Pipeline Review, H1 2015’, provides an overview of the Post Menopausal Osteoporosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post Menopausal Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Post Menopausal Osteoporosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Post Menopausal Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Post Menopausal Osteoporosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Post Menopausal Osteoporosis Overview 8
Therapeutics Development 9
Pipeline Products for Post Menopausal Osteoporosis - Overview 9
Pipeline Products for Post Menopausal Osteoporosis - Comparative Analysis 10
Post Menopausal Osteoporosis - Therapeutics under Development by Companies 11
Post Menopausal Osteoporosis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Post Menopausal Osteoporosis - Products under Development by Companies 15
Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development 16
Amgen Inc. 16
Chronos Therapeutics Limited 17
Eli Lilly and Company 18
Hanmi Pharmaceuticals, Co. Ltd. 19
Merck & Co., Inc. 20
Oncobiologics, Inc. 21
Paras Biopharmaceuticals Finland Oy 22
Pfizer Inc. 23
Radius Health, Inc. 24
Unigene Laboratories, Inc. 25
Post Menopausal Osteoporosis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(aceclofenac + eperisone) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
abaloparatide - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
bazedoxifene acetate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
blosozumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
calcitonin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
denosumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
denosumab biosimilar - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Drugs for Postmenopausal Osteoporosis - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
odanacatib - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
RDC-5 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
romosozumab - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
teriparatide biosimilar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Post Menopausal Osteoporosis - Recent Pipeline Updates 56
Post Menopausal Osteoporosis - Dormant Projects 70
Post Menopausal Osteoporosis - Discontinued Products 71
Post Menopausal Osteoporosis - Product Development Milestones 72
Featured News & Press Releases 72
Jan 29, 2015: Radius Health Announces…

For more information open Post Menopausal Osteoporosis - Pipeline Review, H1 2015.

SKU: GMDHC6630IDB

Original Article: Post Menopausal Osteoporosis - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Post Menopausal Osteoporosis - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Orthopedics
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...